Study details
Enrolling now
E7 TCR-T Cell Immunotherapy for HPV Associated Cancers
Christian Hinrichs
NCT IDNCT05686226ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
20
Study length
about 3.8 years
Ages
18+
Locations
3 sites in MD, NJ
About this study
This trial is testing a new immunotherapy called E7 TCR-T cells to treat advanced cancers caused by the human papillomavirus (HPV). Participants will receive this treatment along with other medications, and their response to treatment will be monitored.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive E7 TCR-T cells
- 2.Take Aldesleukin
PhasePhase 2
DrugAldesleukin
Primary goalTumor response
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
aldesleukin
Endpoints
Primary: Tumor response
Secondary: Adverse Events
Body systems
Oncology